Technical brochure FlowLac

Similar documents
Technical brochure Milled and sieved lactose

Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate

EMCOMPRESS. Calcium Hydrogen Phosphate, Ph.Eur., E 341(ii) Dibasic Calcium Phosphate, USP/NF, FCC. A Proven Excipient for more than 60 Years

Roller Compaction: New trends, challenges and solutions

Maximizing Roller Compaction Benefits with Proper Excipient Selection

Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?

PHARMACEUTICAL PACKAGING

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma

Outline. Opportunities Overview of ASAP Areas of Application ASAP Proposal to Regulators Summary

FRAUNHOFER INSTITUTE FOR CERAMIC TECHNOLOGIES AND SYSTEMS IKTS CENTER OF COMPETENCE POWDER TECHNOLOGY

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms

avitech technical bulletin

GUIDELINE FOR THE STABILITY TESTING

Scientific and Regulatory challenges in Quality by Design (QbD) submissions

Pharma Ingredients & Services. Ludiflash. Technical Information

Your partner in the pharmaceutical industry

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

Int. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries

How to Identify Critical Quality Attributes and Critical Process Parameters

COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS

QbD implementation in Generic Industry: Overview and Case-Study

Measuring and understanding. of powders with the FT4 Powder Rheometer. freemantechnology

Roller Compaction Feasibility for New Drug Candidates

Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)

Manufacturing of Low Fill Weight Capsules Using a Nozzle Dosator Capsule Filling Machine

Oral Dosage Formulation Development

Agilent TRS100 Raman. Quantitative Pharmaceutical Analysis System

NISSO HPC for Pharmaceutical Applications

Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products Guidance for Industry

AEROPERL Granulated fumed oxides

Pharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

Pharma Silica Insights

Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components

Cohesiveness and Flowability Properties of Silica Gel Powder

1. Master Batch Record Approvals Name Signature Date Originator

USP Hypromellose Phthalate

Compression Physics in the Formulation Development of Tablets

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

R&D TO PRODUCT: HOW TO REDUCE COSTLY SCALE-UP PROBLEMS

PLANKSTADT EXPERTS TAKING CARE

Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets)

Formulation and Evaluation of Oro-Dispersible Tablets Containing Meclizine Hydrochloride

The Pelletizing of Industrial Acceptable Magnetite Pellets with Bentonite Clay as Binding Agent

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.

Public Assessment Report. Scientific discussion. Lacidipine Double-e Pharma 2 mg, 4 mg and 6 mg film-coated tablets. (lacidipine)

CGMP Requirements for Investigational Products

Formulation Development

Public Assessment Report Scientific discussion. Lueva (Desogestrel) SE/H/1135/01/DC

On-Demand Manufacturing of Pharmaceuticals

Direct Compression Microcrystalline Cellulose Grade 12 versus Classic Grade 102

TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Approaches to the formulation of poorly soluble drugs

ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS

DIRECTLY COMPRESSIBLE MEDICATED CHEWING GUM (MCG) FOR STAYING ALERT

Indonesia.

Testosterone 20 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier

ARIA FLUID BED PROCESSOR

PURALOX /CATALOX High purity activated aluminas

Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification

WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability

Pharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications

Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production

Product Quality Control of a HME Co-Extrudate Using a Raman Imaging Microscope

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Process Validation And Risk Assessment Study of Loratadine Tablet

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Detection and Quantification of Amorphous Content in Pharmaceutical Materials

Direct compression of cushion layered ethyl cellulose coated extended release pellets into rapidly disintegrating tablets

IPWEA/WALGA Specification for the supply of recycled road base

Formulation and Evaluation of Gastro retentive Bilayer Tablets- Glimepiride as Sustained Release and Lisinopril as Immediate Release

Public Assessment Report. Scientific discussion. Tacrolimus Sandoz 2 mg and 0.75 mg, capsules, hard. (tacrolimus) NL/H/1341/ /DC

Public Assessment Report Scientific discussion. Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC

Regulatory Assessment

Fine Chemicals. Aluminium Brazing Fluxes

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Successful Tableting Supplement. Continuous Tableting MODUL Q A-Type Tooling. engineering for a better world

ISO INTERNATIONAL STANDARD. Dentistry Mercury and alloys for dental amalgam. Art dentaire Mercure et alliages pour amalgame dentaire

Understanding Materials Flowability (Part I) BSH&E SEMINAR

International Journal of Generic Drugs

Siemens AG All rights reserved.

PREFORMULATION STUDIES FOR DIRECT COMPRESSION SUITABILITY OF CEFUROXIME AXETIL AND PARACETAMOL: A GRAPHICAL REPRESENTATION USING SeDeM DIAGRAM

Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire

ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Annexes

Continuous Manufacturing: An Industry View

AEROPERL Granulated fumed oxides. Technical Information 1341

Stability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages.

Powder Processing Equipment - General Catalog

Coathylene Polymer Powders

White Pigments for Flexible Packaging Inks

SIPERNAT and AEROSIL products in the food industry. Industry Information II 2129

Functionalized Calcium Carbonate (FCC) FCC: Newly developed structured minerals as multifunctional excipients

DISCLAIMER. This document is current at the date of downloading. Hunter Water may update this document at any time.

Transcription:

L W TABLETING DIRECT COMPRESSION SPRAY-DRIED LACTOSE AC Technical brochure FlowLac

MEGGLE spray-dried lactose grades for direct compression: FlowLac General information Direct compression (DC) tablet manufacture is a popular choice because it provides the least complex, most cost effective process to produce tablets compared to other tablet manufacturing approaches. Manufacturers can blend APIs with excipients and compress, making dosage forms simple to produce [1, 2]. DC technology and the use of modern tableting equipment require that excipients and APIs form a compactible mixture with excellent flowability and low particle segregation tendency [3]. In the pharmaceutical industry, lactose is one of the most commonly used excipients; however, like many other excipients, lactose may not be suitable for direct compression without modification due to insufficient powder flow or/and compaction properties (Figure 1). In the early 196 s, the introduction of spray-dried lactose changed tablet manufacturing processes and increased direct compression tableting possibilities [4]. Today, MEGGLE is a leading spray-dried lactose manufacturer with the FlowLac brand. Product description FlowLac is produced by spray-drying a fine milled alpha-lactose monohydrate suspension. When lactose is spray-dried, the rapid water evaporation causes amorphous lactose to form [5]. Most commercially available, spray-dried lactose products contain 1 to 15 % amorphous lactose at the time of manufacture, depending on the solids content and process conditions. Lactose performance Flowability/compressability High WG DC Compared to crystalline alpha-lactose monohydrate, FlowLac s compactability is superior. Unlike alpha-lactose monohydrate and anhydrous beta-lactose, which are known to exhibit brittle fracture during compaction, amorphous lactose plastically deforms. Therefore, due to the synergistic plastic and brittle nature of amorphous and crystalline forms in spray-dried lactose, the result is superior compactability [6]. Powder flow WG DG Low Powder compressability High Figure 1: Powder blend compressability and flowability requirements for various tableting technologies (DC is direct compression, WG is wet granulation, DG is dry granulation) [3]. FlowLac 1 is the standard grade for spray-dried lactose, providing excellent flowability and extraordinary compactability compared to other lactose grades. FlowLac 9 was developed to provide greater compactability compared to FlowLac 1 by optimizing the amorphous lactose content. In addition, the particle size distribution makes FlowLac 9 virtually dust-free. 2 MEGGLE Spray-dried lactose FlowLac 3-214

Regulatory & quality information FlowLac 9 and FlowLac 1 are MEGGLE s trade names for spray-dried alpha-lactose monohydrate and comply with the current harmonized Ph.Eur., USP-NF, and JP monographs. Specifications and regulatory documents can be downloaded from www.meggle-pharma.com. Our pharma-dedicated production facility in Wasserburg, Germany is certified according to DIN ISO 91:28, has implemented cgmp according to the Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients and USP General Information Chapter <178>. The Wasserburg facility demonstrates MEGGLE s complete lactose production capability range, including sieving, milling, agglomeration, spray-drying, and co-processing. Additionally, MEGGLE is a member of IPEC (International Pharmaceutical Excipients Council). Application FlowLac was developed especially for direct compression processes. The following chart provides recommended areas of application. Low to medium dose DC formulations Formulations with poorly flowing API s Capsule and sachet filling MEGGLE invests considerably in raw material resource sustainability, production standards, efficiency and is actively engaged in environmental protection. Lactose meeting pharmaceutical standards is our first priority. BENEFITS FlowLac Superior flowability Excellent compactability Low hygroscopicity and high stability Fast disintegration times MEGGLE Spray-dried lactose FlowLac 3-214 3

Particle size distribution (PSD) Figure 2 shows typical laser diffraction particle size distribution data for MEGGLEs spray-dried lactose grades, FlowLac. FlowLac 9 offers a tighter particle size distribution compared to FlowLac 1 because of reduced fines content. Figure 3 depicts the specified PSD range and typical average values by air jet sieving. These parameters are constantly monitored through in-process-control (IPC) testing and are part of FlowLac s particle size distribution specification. Typical particle size distribution (Laser diffraction) Spray-dried lactose grades, cumulative PSD Cumulative distribution Q3(x)/% 1 9 8 7 6 5 4 3 2 1 1 1 1 1 Particle size (µm) FlowLac 9 FlowLac 1 Typical particle size distribution (Laser diffraction) Spray-dried lactose grades, distribution density Distribution density q3lg(x) 2.5 2. 1.5 1..5 1 1 1 1 Particle size (µm) FlowLac 9 FlowLac 1 Figure 2: Typical cumulative PSD and distribution density of MEGGLE s FlowLac 9 and FlowLac 1. Analyzed by Sympatec /Helos & Rodos particle size analyzer. Figure 3: Specified PSDs for MEGGLE s spray-dried lactose grades by air jet sieve in bold letters. Typical values obtained from a permanent in-process-control are shown for orientation. Sieve data spray-dried lactose Lactose type FlowLac 9 FlowLac 1 specified/typical specified/typical Particle size distribution < 32 µm NMT 5 %/2 % NMT 1 %/5 % Method: < 1 µm 25 4 %/29 % 2 45 %/32 % Air jet sieving < 2 µm NLT 85 %/91 % NLT 8 %/87 % < 25 µm /99 % /97 % 4 MEGGLE Spray-dried lactose FlowLac 3-214

Batch-to-batch consistency Batch-to-batch consistency for all lactose products can be attributed to MEGGLE s long history and experience in lactose manufacture, and broad technical expertise. Constant in-process and final product testing ensures consistency and quality (Figure 4). Batch-to-batch consistency particle size distribution spray-dried lactose FlowLac 9 Passing through 1 sieve (%) 8 Batch-to-batch consistency particle size distribution spray-dried lactose FlowLac 1 Passing through 1 sieve (%) 8 6 6 4 4 2 2 Particle size (µm) < 32 < 1 < 2 < 25 Specified NMT 5 % 25 4 % NLT 85 % Mean IPC value (%) 1.9 28.5 91.1 98.9 SD (%).9 1.6 1.4.5 Particle size (µm) < 32 < 1 < 2 < 25 Specified NMT 1 % 2 45 % NLT 8 % Mean IPC value (%) 4.5 31.6 87. 97. SD (%).9 1.8 1.6.8 Figure 4: Particle size distribution batch-to-batch consistency of FlowLac by air jet sieving. Data obtained from a permanent in-process-control (IPC) of subsequent batches over 12 months. MEGGLE Spray-dried lactose FlowLac 3-214 5

Isotherms MEGGLE s spray-dried lactose products do not adsorb significant amounts of water below 2 C/8 % relative humidity. Figure 5 shows sorption and desorption isotherm for FlowLac 9. Sorption isotherm (Dynamic vapor sorption at 2 C) FlowLac 9 Weight change (%) 1..9.8.7.6.5.4.3.2.1. 2 4 6 8 1 Relative humidity (%) Sorption Desorption Figure 5: Sorption-desorption isotherm of spray-dried lactose, using FlowLac 9 as an example. While pure, crystalline lactose monohydrate demonstrates equi valent equilibrium moisture content during sorption and desorption, spray-dried lactose demonstrates hysteresis, having different equilibrium moisture content upon sorption and desorption. The hysteresis is caused by the conversion of lactose from the amorphous to crystalline form. Therefore significant changes in relative humidity during storage should be avoided. For regions with very high relative humidity, MEGGLE offers and recommends non-water-permeable packaging materials, such as aluminum inliners, to retain optimal material functionality. Figure 6 demonstrates FlowLac 1 s superior compactability at different storage conditions if packed in aluminum inliners instead of polyethylene inliners. Reduction of compactability depending on storage conditions and packaging material FlowLac 1 Reduction of compactability (%) 5 4 3 2 37 1 7 6 24 months, 25 C/6 % r. H. 6 months, 4 C/75 % r. H. Storage conditions Aluminium inliner Polyethylen inliner 45 Figure 6: Reduction of compactability of FlowLac 1 depending on storage conditions and packaging material. Scanning electron micrograph (SEM) Due to the spray-drying process, FlowLac has a spherical agglomerate shape, consisting of small alpha-lactose monohydrate crystals bound by amorphous lactose (Figure 7). FlowLac s spherical shape and narrow particle size distribution result in excellent flow characteristics. 8 µm 8 µm FlowLac 9 FlowLac 1 Figure 7: SEM images of various spray-dried MEGGLE lactose grades. 6 MEGGLE Spray-dried lactose FlowLac 3-214

Flowability Spray-dried lactose Flowability index (mm) 25 2 Poor flow 15 Moderate flow 1 Good flow 5 Very good flow Excellent flow FlowLac 9 FlowLac 1 Tablettose 7 SpheroLac 1 GranuLac 7 Figure 8: Flowability index of FlowLac grades compared to other lactose grades. Functional related characteristics Powder flow It is well-known that particle size and shape influence powder flowability. Particles less than 1 μm tend to be more cohesive and less freely flowing, whereas larger, denser particles tend to be more freely flowing. Particle morphology also significantly affects powder flow characteristics. Figure 8 demonstrates that particle shape and structure are more important than the particle size distribution alone when flowability is considered. Due to its spherical shape, spray-dried lactose possesses the best flowability of all available lactose grades, resulting in a low flowability index FI (powder through an orifice) compared to sieved (SpheroLac 1) or milled (GranuLac 7) lactose. Flowability Spray-dried lactose Angle of repose ( ) Density bulk (g/l) Density tapped (g/l) Hausner ratio Compactability Spray-dried lactose Tablet hardness (N) 45 4 35 3 25 2 15 1 5 5 1 15 2 25 3 35 4 45 Compaction force (kn) Tablet press: Kilian Styl one 15ML, Tablets: Ø 11,3 mm, 5 mg FlowLac 9 FlowLac 1 DC agglomerated lactose grade Carr s index (%) FlowLac 9 27 56 67 1.2 16.42 FlowLac 1 28 59 71 1.2 16.9 Figure 9: Typical powder technological flowability values for FlowLac grades. Flowability can also be described by the Hausner ratio, Carr s index, or angle of repose. A Hausner ratio below 1.25 or Carr s index below 2 indicates that powders are freely flowing. Angle of repose describes good flowability between 31 35, and in general, worsens with steeper angles. Figure 9 shows typical flowability indices for FlowLac grades, indicating the excellent flowability possessed by spray-dried lactose. Compactability Figure 1 shows that tablets made with FlowLac achieve greater tablet hardness compared to DC alpha-lactose monohydrate. This results from the plastically deforming amorphous lactose present in spraydried lactose, which is not present in agglomerated lactose. The plastically deforming amorphous lactose and brittle crystalline lactose work synergistically to increase compactability. FlowLac 9 s higher amorphous content provides superior compactability when compared to FlowLac 1. Due to the reduced compaction forces required during tableting, tooling wear can be decreased while tablet hardness can be increased. Figure 1: Force-hardness profile of FlowLac grades compared to DC agglomerated lactose. Packaging and shelf life FlowLac Size Material Shelf life FlowLac 9 36 months Corrugated carton box with an aluminium laminated inliner FlowLac 1 25 kg 24 months FlowLac 1 Paper bag with PE-EVOH-PE inliner 18 months Figure 11: Packaging and shelf life of MEGGLE s spray-dried lactose grades. Packaging and shelf life Packaging material complies with Regulation (EC) No. 1935/24 and 21 CFR 174, 175, 176, 177 and 178. Stability tests have been performed according to ICH guidelines and an ongoing stability program is implemented. Figure 11 provides an overview about packaging size and material, and product shelf life. MEGGLE Spray-dried lactose FlowLac 3-214 7

Literature [1] Meeus, L. (211). Direct Compression versus Granulation. Pharmaceutical Technology, 23(3). [2] Kristensen, H. G., & Schaefer, T. (1987). Granulation: A Review on Pharmaceutical Wet-Granulation. Drug Development and Industrial Pharmacy, 13(4 5), 83 872. [3] Mîinea, L. A., Mehta, R., Kallam, M., Farina, J. A., & Deorkar, N. (211). Evaluation and Characteristics of a New Direct Compression Performance Excipient, 35(3). [4] Gohel, M. C., & Jogani, P. D. (25). A review of co-processed directly compressable excipients. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques, 8(1), 76 93. [5] Roos, Y. H. (22). Importance of glass transition and water activity to spray drying and stability of dairy powders. Le Lait, 82(4), 475 484. [6] RUANGCHAYAJATUPORN, J., AMORNSAKCHAI, T., SINCHAIPANID, N., & MITREVEJ, A. (n.d.). Compaction behavior and optimization of spray-dried lactose with various amorphous content. Journal of drug delivery science and technology, 21(2), 175 181. MEGGLE App: MEGGLE Consultant MEGGLE Group Wasserburg BG Excipients & Technology Megglestrasse 6 12 83512 Wasserburg Germany Phone +49 871 73 476 Fax +49 871 73 32 service.pharma@meggle.de www.meggle-pharma.com MEGGLE warrants that its products conform to MEGGLE s written specification and makes no other expressed or implied warrantees or representations. For any specific usage, the determination of suitability of use or application of MEGGLE products is the sole responsibility of the user. The determination of the use, application, and compliance of this product with regard to any national, regional, or local laws and/or regulations is the sole responsibility of the user, and MEGGLE makes no representation with regards to same. Nothing herein shall be construed as a recommendation or license to use the product or any information that conflicts with any patent or intellectual property of MEGGLE or others and any such determination of use is the sole responsibility of the user. MEGGLE US 3-12-214 Sai